Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Fig. 1

Enrollment of patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP4i). A total of 15,606 T2DM patients treated with SGLT2i were compared with 12,383 patients treated with DPP4i from June 1, 2016 to December 31, 2018. AF = atrial fibrillation; DPP4i = dipeptidyl peptidase-4 inhibitor; SGLT2i = sodium glucose cotransporter 2 inhibitor; T2DM = type 2 diabetes mellitus

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840